On February 4, the winner of the Nobel Prize in Physiology and Medicine in 1996, Peter C. Doherty, results in the efficacy of the Sputnik V vaccine against COVID-19. Assimilation, assuming that the possible modifications to the dose before the new variants of the virus do not cause deficiencies in its creators.
In statements to the TASS, Doherty news agency, the use of viral vectors in the manufacture of the pharmacy developed by the Gamaleya Center.
“The efficiency of the Sputnik V caravan – more than 90% – is very good, and in addition, Russia has a long history of developing a good caravan. The strategy for the use of adenovirus vectors is well known, and is the only one used in Sputnik. By supuesto, if the virus changes significantly as a result of the mutation, the creators of the vaccine tend to ‘correct’ a small amount of the drug, but will not be difficult”, Commented by the specialist.
Following an intermediate phase 3 analysis of clinical trials, published on March 2 in the medical review The Lancet, the vaccine rushed Sputnik V against coronavirus had a general efficacy of 91.6%.
The annual publication is that in said dichos, 21,977 adults participate, that between September 7 and November 24, 2020, there will be a series of random alterations to the vaccine group (16,501 people) and placebo (5,746). A total of 19,866 volunteers received the necessary doses for the immunization, and between them, only 78 cases of COVID-19 were confirmed.